BIIB Biogen Inc.

BEARISH Impact: 7/10 PRESS-RELEASE
Horizon immediate Filed May 21, 2026 Processed 24d 12h ago Wire GlobeNewswire
Press release: contract
Latest settled — T+5d
BIIB ▼ -0.84% at T+5d
SHORT call ✓ call won +0.84% · α vs SPY +2.50% · entry $193.85 → $192.22
Next anchor: T+20d in 7d
Last close $200.05 (close Jun 12) · -3.20% from $193.85 entry (call sign-flipped)
Entry anchored
May 21, 2026
via day open
T+1d
-0.40%
call +0.40% · α +0.99%
$193.07
settled 24d ago
T+5d
-0.84%
call +0.84% · α +2.50%
$192.22
settled 17d ago
T+20d
—
call — · α —
—
in 7d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 for idiopathic Parkinson's disease will be discontinued, a significant setback for Biogen's pipeline.

Actionable Insight

Expect negative price reaction for BIIB and DNLI on the trial failure and discontinuation. Monitor for any further pipeline updates or strategic shifts from Biogen. Denali's independent BEACON study in LRRK2 carriers may provide partial offset.

Key Facts

  • Phase 2b LUMA study of BIIB122 did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
  • Secondary endpoints also did not show benefit with BIIB122.
  • Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
  • Denali continues Phase 2a BEACON study in LRRK2 variant carriers independently.
  • BIIB122 was generally well tolerated with >90% kinase inhibition achieved.

Financial Impact

Development costs and potential write-offs for BIIB122, but no specific dollar amounts disclosed in the press release.

r&d_expensepipeline_value

Risk Factors

  • Loss of potential revenue from BIIB122 in idiopathic Parkinson's disease.
  • Reduced investor confidence in Biogen's pipeline efficiency.
  • Potential impairment of collaboration assets.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3299820
24 reports for BIIB
Performance horizon
91% Hit rate 10 of 11 directional calls best @ T+60▲ +18.00%May 31, 2026
Filters
Rows
Reports for BIIB — sortable, filterable
Type Now
Jun 13, 2026
1d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$176.40 awaiting T+1awaiting T+1—$200.05 (+13.41%)
Jun 8, 2026
6d ago
ANALYST-UPGRADE
BULLISH ★ 2/10
$194.60 awaiting T+1awaiting T+1—$200.05 (+2.80%)
Jun 4, 2026
11d ago
Press Release
NEUTRAL ★ 5/10
$195.82 $195.30▼ −0.27%▲ +2.33%$200.05 (+2.16%)
Jun 1, 2026
14d ago
Press Release
MIXED ★ 5/10
$192.22 $188.66▼ −1.85%▼ −2.00%$200.05 (+4.08%)
May 31, 2026
14d ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$156.63 $154.99▼ −1.05%▼ −1.18%$200.05 (+27.72%)
May 22, 2026
23d ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$190.12 $187.84▼ −1.20%▼ −0.81%$200.05 (+5.22%)
May 21, 2026
24d ago
Press Release
BEARISH ★ 7/10
$193.85 $193.07▲ +0.40%▲ +0.99%$200.05 (−3.20%)
May 20, 2026
25d ago
ANALYST-UPGRADE
MIXED ★ 3/10
$183.33 $185.18▲ +1.01%▲ +1.66%$200.05 (+9.12%)
May 14, 2026
4w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$178.76 $180.47▲ +0.96%▲ +0.18%$200.05 (+11.91%)
May 14, 2026
4w ago
Press Release
BULLISH ★ 7/10
$191.26 $192.32▲ +0.55%▲ +1.78%$200.05 (+4.60%)
Showing 10 of 24

US Market Status

Market Closed — Opens in 3h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access